7% of US physio clinics are now PE-owned

Every consolidation story in this specialty starts the same way: a competitor down the road gets bought, a colleague sells to a regional group, and you are left guessing how much of the map is still independent. A peer-reviewed study now has an actual answer. Private equity firms held 2,591 outpatient physical therapy clinics in the United States as of 2024 (Journal of the American Academy of Orthopaedic Surgeons, published ahead of print, October 2025). Set against an industry estimated at more than 37,000 clinics nationwide, that works out to roughly 7% of the market.

Seven percent sounds like a market still mostly in independent hands, and it is. The number that should actually hold your attention is not the share, it is the slope behind it. The same study counted 4 PE-backed deals in outpatient physical therapy in 2010. By 2023, that had grown to 175 deals in a single year. Divide 175 by 4 and the annual deal pace is nearly 44 times what it was thirteen years ago.

What the study actually measured

The JAAOS study is a cross-sectional analysis of PE acquisitions of US physical therapy practices between January 1, 2010, and December 31, 2024, built on PitchBook acquisition records and checked against the 2024 Medicare Care Compare provider database to estimate practice counts. That combination, a deal-tracking dataset cross-checked against a federal provider registry, is a stronger basis than the practice-broker and PE-advisory blogs that dominate search results for this topic, and it is the same standard this site applied when the dental AI spend figure could not be verified in July and was left out rather than substituted.

One access note. The full JAAOS text sits behind a subscription wall, and direct access attempts to the publisher's page, Ovid, and ResearchGate were all blocked this session. The core figures, the 4-to-175 deal growth, the 2,591-clinic 2024 total, and the 91.1% add-on share below, are consistent across three independent secondary reports of the same study, which is the level of corroboration this site has previously accepted when a primary fetch fails but the study itself is peer-reviewed and named.

So what for you: this is not a vendor's market-sizing estimate dressed up as research. It is the same category of source APTA and CMS data occupy elsewhere on this site, and it is worth citing by name if a patient, a referring physician, or your own accountant asks where the consolidation numbers come from.

The 7% calculation, and what surrounds it

The headline math is simple. 2,591 divided by an estimated 37,000-plus outpatient clinics nationwide (Tupelo, physical therapy industry overview, September 2025) gives roughly 7%. No single company holds more than 10% of the national market on that same estimate, and the 50 largest PT organizations combined capture only about 29%, leaving tens of thousands of clinics still independently owned.

That source also states that the top six therapy companies operated approximately 4,949 clinics in 2024, about 9.7% of all clinics, generating more than $4 billion in revenue. Worth flagging directly: 4,949 clinics at 9.7% implies a total market of roughly 51,000 clinics, which does not reconcile cleanly with the same source's separate 37,000-plus estimate. The two figures come from the same industry overview and were not independently audited against each other. Read every market-share number in this article as directional, correct to within a few percentage points, not as a precise count.

What is not in dispute is which platforms are doing the buying. Upstream Rehabilitation operates more than 1,200 clinics across 28 states, Athletico more than 900, and Confluent Health more than 650 across 35 states (company websites, 2026, self-reported and not independently audited). None of them is close to national dominance individually. Collectively, platforms like these are the buyers behind the 44-fold jump in annual deal count.

So what for you: a 7% national share means your specific market is very unlikely to be majority-consolidated yet. It also means the deal pace has thirteen years of runway still ahead of it if it continues on the same curve, and the study's own window only runs to the end of 2024.

The number that matters more than the share

Here is the finding that should change how you read every acquisition offer that lands in your inbox. Of the PE deals identified in the JAAOS study, 91.1% were add-on acquisitions, meaning an already-established PE-backed platform bought a clinic that was already open and operating, rather than a new location being built from scratch.

Private equity is not growing the supply of physical therapy clinics in the United States. It is buying the supply that independent owners already built, one clinic at a time. The people selling into that 91.1% figure are, overwhelmingly, owner-therapists at or near retirement age, without an internal succession plan, taking the only exit offer that showed up. Nearly half of physical therapists nationally are 50 or older, and the industry is already projected to run a shortfall of roughly 16,000 practitioners a year through 2030, which is exactly the demographic profile that produces a steady stream of sellers regardless of what any individual practice is worth clinically.

So what for you: the acquisition wave is not evidence that independent physical therapy is losing on merit. It is evidence that a specific, predictable group of owners without a succession plan is taking the exit that exists. If you are not in that group, the 91.1% figure is not describing your situation, and reacting to consolidation anxiety by assuming you are next is reading the data backward.

What private equity is actually buying

Ask what a platform like Upstream or Confluent Health does differently on day one after an acquisition, and the answer is rarely a change in treatment technique. It is standardized scheduling, standardized billing and collections, standardized patient intake and recall, and a shared technology stack applied across every site in the network. That is the same pattern already documented on this site for physical therapy specifically: Ivy Rehab's rollout of an AI ambient scribe network-wide, standardizing documentation across an entire multi-site roster rather than leaving each clinic to configure its own approach.

That is the call worth making plainly. The advantage a PE-backed group buys with acquisition capital is operational consistency, not better clinical care. Consistency is a system, not a headcount, and systems can be bought without selling anything.

So what for you: if the fear behind consolidation anxiety is that a bigger, better-resourced competitor is about to out-operate you, name the actual mechanism. It is not superior therapists. It is fewer dropped calls, faster claim turnaround, and a recall list that does not depend on one person's memory.

The layer you can close without selling

This is where the calculation turns practical. The standardization layer a PE platform buys with acquisition capital and a corporate IT team is now available to a one-site or two-site independent practice as a monthly subscription. AI-driven billing and revenue cycle tools already close the same claim-turnaround and collections gap a platform's centralized billing office exists to solve. Prior authorization currently costs the average practice roughly $34,000 and 700 staff hours a year, the exact category of overhead a multi-site group absorbs by spreading it across more locations and an independent practice absorbs by hiring, or now, by automating.

None of this closes the capital gap between a single clinic and a 900-location platform, and it should not be sold to you as though it does. What it closes is the specific gap that makes acquisition attractive in the first place: the sense that running a smooth, consistent, well-documented practice requires scale you do not have. Multi-site AI standardization in physical therapy already runs at platform scale, and the tools behind it are not platform-exclusive.

The direct recommendation: do not wait for a decision about selling to force the operational question. Audit your own billing turnaround, no-show rate, and phone answer rate now, against what a standardized multi-site group would report, and close the largest gap first. That is a decision available to a practice of any size, this quarter, independent of anyone's acquisition offer.

If you want that comparison done properly rather than estimated from a blog post, our AI Opportunity and Growth Assessment benchmarks a practice's admin operations against what standardized multi-site groups actually run, and prices what closing the gap costs. You can also book a 20-minute call to talk through where your practice sits before any acquisition conversation starts.

Related: Physio AI already scales past 650 clinics  ·  The physio AI billing verdict  ·  Prior authorization's true cost for PTs

Core figures (4 to 175 annual PE deals, 2,591 PE-affiliated clinics by 2024, 91.1% add-on acquisitions) are from a cross-sectional study published ahead of print in the Journal of the American Academy of Orthopaedic Surgeons, October 2025 (DOI 10.5435/JAAOS-D-25-00650), built on PitchBook acquisition data checked against the 2024 Medicare Care Compare provider database. Direct access to the full text was blocked at the publisher, Ovid, and ResearchGate this session; the figures above are corroborated consistently across three independent secondary reports of the same study rather than confirmed against the primary text directly, and should be read with that caveat. The 37,000-plus total clinic estimate, the sub-10% single-company share, the 50-largest-organizations 29% share, and the top-six-company 9.7% share are from an M&A advisory industry overview (Tupelo, September 2025), not independently audited, and contain an internal inconsistency between the 37,000-plus and roughly 51,000-clinic estimates implied by different figures in the same source, flagged above. Named platform clinic counts are self-reported on company websites in 2026. This article is for informational purposes only and does not constitute clinical, legal, or financial advice.